Table 3 Tocilizumab compared to control cohort based on propensity-weighteda models for quality of life patient-reported outcomes after adjusting for baseline values and aGVHD (grades II–IV).

From: The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill

Assessment

Day 28

Day 100

Day 180

Estimate (95% CI)

P value

Estimate (95% CI)

P value

Estimate (95% CI)

P value

Depression

4.73 (0.64, 8.81)

0.02

1.54 (−2.81, 5.88)

0.49

4.41 (−0.59, 9.40)

0.08

Anxiety

1.64 (−0.16, 3.44)

0.07

2.82 (0.86, 4.78)

0.005

1.76 (−0.48, 4.00)

0.12

Fatigue, intensity

0.36 (−0.41, 1.13)

0.36

0.18 (−0.66, 1.01)

0.68

0.89 (−0.05, 1.82)

0.06

Fatigue, duration

1.13 (−0.56, 2.83)

0.19

1.11 (−0.70, 2.93)

0.23

1.22 (−0.85, 3.30)

0.25

Fatigue, interference

−0.31 (−1.16, 0.54)

0.47

−0.27 (−1.18, 0.64)

0.56

−0.37 (−1.41, 0.67)

0.48

Pain, intensity

1.22 (0.49, 1.96)

0.001

0.27 (−0.53, 1.07)

0.50

0.98 (0.07, 1.88)

0.04

Pain, interference

0.11 (−0.78, 0.99)

0.81

−0.15 (−1.13, 0.82)

0.75

0.08 (−1.02, 1.19)

0.88

Sleep

1.32 (−0.30, 2.94)

0.11

1.47 (−0.23, 3.17)

0.09

2.46 (0.54, 4.38)

0.01

  1. aPropensity scores were obtained using a logistic regression model with age, sex, BMI, CMV status, conditioning regimen, and donor type as predictors of study group.
Back to article page